
Loading, please wait...

Loading, please wait...

Clinicians often evaluate the long-term reliability of breast implants to ensure patient satisfaction and health. Recent findings from a retrospective cohort study provide crucial insights into the PERLE breast implant safety profile over a five-year period. This study monitored 738 patients who underwent primary or secondary bilateral breast augmentation and augmentation-mastopexy. Specifically, researchers followed 1,476 implants to assess complications and re-operation rates. The implants featured a unique surface roughness of 5 μm, designed to improve tissue integration.
The results highlighted remarkably low rates of major complications across various surgical planes. For example, the overall rate of capsular contracture per patient was only 0.5% in the augmentation group. Moreover, the per-implant rate for capsular contracture stood at just 0.3%. Notably, subfascial and submuscular placements showed zero cases of contracture during the five-year observation period. Consequently, these figures suggest that the shell architecture and gel cohesivity effectively mitigate common postoperative issues.
Data regarding re-operation rates provide a clear picture of clinical durability for surgeons and patients alike. The 5-year re-operation rate for implant-related complications was 2.5% for the augmentation group. In contrast, the augmentation-mastopexy group experienced a slightly higher complication rate of 5.5%. However, no cases of implant rupture or rippling occurred during the entire follow-up. Additionally, researchers reported no instances of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), which is a significant safety milestone.
Furthermore, the rate of implant malposition remained low at 0.7% for primary augmentations. These outcomes confirm that modern manufacturing techniques can improve the clinical course of aesthetic procedures. As a result, the PERLE implant demonstrates a safety profile that aligns with the highest standards in plastic surgery today.
Based on five-year clinical data, the risk is extremely low. The per-implant rate is approximately 0.3%, which is considered superior to many traditional textured or smooth implants.
No cases of BIA-ALCL or implant rupture were reported in the five-year follow-up study involving 1,476 implants, suggesting high long-term biocompatibility.
The re-operation rate for augmentation alone was 2.5% at five years. However, patients undergoing combined augmentation-mastopexy had a complication rate of 5.5%, reflecting the increased complexity of the procedure.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. It should not be used as a substitute for professional diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Lucocq J et al. Five-year Results of the PERLE Implant in Breast Augmentation and Augmentation-mastopexy. Aesthet Surg J. 2026 Apr 15. doi: undefined. PMID: 41986897.
Ng ZY, Honeyman C, Shoaib T. Single-Institution Early Experience With a New, Smooth, Opaque, and Round Breast Implant Over a 2-Year Period. Aesthetic Surgery Journal Open Forum. 2023;5:ojad090.
GC Aesthetics. GC Aesthetics Announces Decade-Long Clinical Evaluation of PERLE Breast Implants. Published December 18, 2024.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A retrospective cohort study of 738 patients reveals long-term safety data for PERLE implants in primary and secondary breast surgery over five years....
6 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today